Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | STAT1 | P42224 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9601170 | 0.84 | TRPA1 (0.47) | SMN1; SMN2LMNARAB9ANPC1MAPT | |
| SCHEMBL5565180 | 0.84 | TNF (0.43) | SMN1; SMN2RECQLMAPK10LMNAHTT | |
| SCHEMBL5500566 | 0.84 | ESR1 (0.47) | SMN1; SMN2LMNAMAPTHTTNPSR1 | |
| SCHEMBL5493928 | 0.82 | PRKCA (0.46) | SMN1; SMN2LMNARAB9ANPC1HTT | |
| SCHEMBL3056830 | 0.81 | HSD17B13 (0.40) | SMN1; SMN2RECQLMAPK10LMNANPC1 | |
| SCHEMBL9253194 | 0.81 | LMNA (0.43) | SMN1; SMN2RECQLMAPK10LMNA | |
| SCHEMBL9252072 | 0.81 | TNF (0.43) | SMN1; SMN2RECQLMAPK10LMNA | |
| SCHEMBL13646422 | 0.81 | TNF (0.56) | SMN1; SMN2LMNAMAPTHTTNPSR1 | |
| SCHEMBL9366964 | 0.80 | MMP13 (0.52) | SMN1; SMN2RECQLMAPK10POLB | |
| SCHEMBL11964120 | 0.80 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNARAB9ANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-8293902-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2012-10-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | HENNEQUIN LAURENT FRANCOIS ANDRE (FR) | 2012-02-23 | — | — | US | disclosed |
| US-7989460-B2 | potent kinase insert domain-containing receptor (KDR) inhibitors with improved selectivity and pharmacokinetics; VEGF (vascular endothelial growth factor) inhibitors; cancer and rheumatoid arthritis; e.g. 7-(2-[4-(acetylmethyl)piperazin-1-yl]ethoxy)-6-methoxy-4-[(2-methyl-1H-indol-5-yl)oxy]quinazoline | ASTRAZENECA AB (SE) | 2011-08-02 | — | — | US | disclosed |
| US-20090156821-A1 | Quinazoline compounds | ASTRAZENECA AB | 2009-06-18 | — | — | US | disclosed |
| US-20080058342-A1 | Quinazoline Derivatives As Angiogenesis Inhibitors | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| US-20080027069-A1 | Quinazoline compounds | ASTRAZENECA AB | 2008-01-31 | — | — | US | disclosed |
| US-7268230-B2 | Quinazoline compounds | ASTRAZENECA AB (SE) | 2007-09-11 | — | — | US | disclosed |
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | disclosed |
| EP-1381599-A1 | QUINAZOLINE DERIVATIVES | Astrazeneca AB (SE) | 2004-01-21 | — | — | EP | disclosed |
| EP-1332141-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2003-08-06 | — | — | EP | disclosed |
| EP-1326859-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | AstraZeneca AB (SE) | 2003-07-16 | — | — | EP | disclosed |
| WO-2002030924-A9 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2003-05-22 | — | — | WO | disclosed |
| WO-2002085895-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002034744-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2002-05-02 | — | — | WO | disclosed |
| WO-2002030924-A1 | QUINAZOLINE DERIVATIVES WITH ANTI-TUMOUR ACTIVITY | ASTRAZENECA AB (SE) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058342-A1 | Quinazoline Derivatives As Angiogenesis Inhibitors | VEGFA, KDR, FLT1 | SMN1; SMN2 3704/4885RECQL 878/4885MAPK10 1659/4885 |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | SMN1; SMN2 4479/4885RECQL 831/4885MAPK10 834/4885 |
| US-20120046300-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, KDR, FLT1 | SMN1; SMN2 3661/4885RECQL 933/4885MAPK10 1772/4885 |
| US-20090156821-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | SMN1; SMN2 4040/4885RECQL 142/4885MAPK10 2943/4885 |
| US-20080027069-A1 | Quinazoline compounds | VEGFA, FLT4, FLT1 | SMN1; SMN2 4040/4885RECQL 142/4885MAPK10 2943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.